Table 3C.
Subgroup analysis according to HAIC regimen (FOLFOX vs RALOX).
| FOLFOX (n = 113) | RALOX(n = 32) | p value | |
|---|---|---|---|
| mRECIST | |||
| Best response (n, %) | |||
| CR | 5 (4.4) | 4 (12.5) | 0.109 |
| PR | 59(52.2) | 14 (43.8) | 0.398 |
| SD | 36 (31.9) | 12 (37.5) | 0.549 |
| PD | 13 (11.5) | 2 (6.2) | 0.523 |
| ORR (CR+PR) | 64 (56.6) | 18 (56.3) | 0.670 |
| DCR (CR+PR+SD) | 100 (88.5) | 30 (93.8) | 0.523 |
| Conversion rate (n, %) | 22 (19.5) | 5 (15.6) | 0.622 |
FOLFOX: HAIC with oxaliplatin, 5-fluorouracil, and leucovorin; RALOX: HAIC with raltitrexed plus oxaliplatin; mRECIST, modified Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.